FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:984-991 October 12, 1995 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The recognition of gastritis due to Helicobacter pylori as a factor of major importance has revolutionized the therapeutic approach to peptic ulcer disease.^1,2 The recurrence of ulcers can be more effectively prevented by a single course of antimicrobial treatment that eradicates H. pylori infection than by the continuous suppression of acid secretion. This concept received important support when a recent Consensus Development Conference of the National Institutes of Health (NIH) recommended that all patients with ulcers who are also infected with H. pylori receive antimicrobial therapy.³ Our review will focus on how to diagnose and treat H. pylori infection in . . . [Full Text of this Article]

The Role of H. pylori in Peptic Ulcer Disease

Diagnosis of Infection

Treatment of Infection

Amoxicillin

Tetracycline

Metronidazole

Clarithromycin

Bismuth

H⁺/K⁺–ATPase Inhibitors

Therapeutic Regimens to Eradicate H. pylori

Triple Antimicrobial Therapy

Double Antimicrobial Therapy

Double Antimicrobial Therapy plus an Antisecretory Drug

A Single Antimicrobial Drug plus an H⁺/K⁺–ATPase Antagonist

Single Antimicrobial Therapy

Which Infected Patients Should Be Treated?

Follow-Up of Patients after Eradication of Infection

Recurrence of Infection after Eradication

Summary

Source Information

From the Center for Ulcer Research and Education of the Veterans Affairs/UCLA Gastroenteric Biology Center, West Los Angeles Veterans Affairs Medical Center, and the Department of Medicine, UCLA School of Medicine, Los Angeles (J.H.W.); and the Medical Service, Veterans Affairs Medical Center, and the Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas (W.L.P.). Drs. Walsh and Peterson are members of the Scientific Advisory Board of the Glaxo Institute of Digestive Health.

Address reprint requests to Dr. Walsh at CURE, Bldg. 115, Rm. 115, West Los Angeles Veterans Affairs Medical Center, Los Angeles, CA 90073.

References

Related Letters:

Treatment of Helicobacter pylori Infection in Peptic Ulcer Disease
Sniffen J. C., Walsh J. H., Peterson W. L.
Extract | Full Text  
N Engl J Med 1996; 334:474, Feb 15, 1996. Correspondence

Use of Veterans Affairs Medical Care by Enrollees in Medicare HMOs
DeVito C. A., Morgan R. O., Virnig B. A.
Extract | Full Text  
N Engl J Med 1997; 337:1013-1014, Oct 2, 1997. Correspondence

This article has been cited by other articles:

• Wallace, J. L. (2008). Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach Digest Itself?. Physiol. Rev. 88: 1547-1565 [Abstract] [Full Text]  
• Guzelian, P. S, Victoroff, M. S, Halmes, N C., James, R. C, Guzelian, C. P (2005). Evidence-based toxicology: a comprehensive framework for causation. Hum Exp Toxicol 24: 161-201 [Abstract]  
• Song, D. H., Rana, B., Wolfe, J. R., Crimmins, G., Choi, C., Albanese, C., Wang, T. C., Pestell, R. G., Wolfe, M. M. (2003). Gastrin-induced gastric adenocarcinoma growth is mediated through cyclin D1. Am. J. Physiol. Gastrointest. Liver Physiol. 285: G217-G222 [Abstract] [Full Text]  
• Suzuki, N., Wakasugi, M., Nakaya, S., Kokubo, N., Sato, M., Kajiyama, H., Takahashi, R., Hirata, H., Ezure, Y., Fukuda, Y., Shimoyama, T. (2002). Catalase, a Specific Antigen in the Feces of Human Subjects Infected with Helicobacter pylori. CVI 9: 784-788 [Abstract] [Full Text]  
• Samra, Z., Shmuely, H., Niv, Y., Dinari, G., Passaro, D. J., Geler, A., Gal, E., Fishman, M., Bachor, J., Yahav, J. (2002). Resistance of Helicobacter pylori isolated in Israel to metronidazole, clarithromycin, tetracycline, amoxicillin and cefixime. J Antimicrob Chemother 49: 1023-1026 [Abstract] [Full Text]  
• Fischbach, L. A, Goodman, K. J, Feldman, M., Aragaki, C. (2002). Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int J Epidemiol 31: 128-139 [Abstract] [Full Text]  
• Suzuki, N., Wakasugi, M., Nakaya, S., Okada, K., Mochida, R., Sato, M., Kajiyama, H., Takahashi, R., Hirata, H., Ezure, Y., Koga, Y., Fukuda, Y., Shimoyama, T. (2002). Production and Application of New Monoclonal Antibodies Specific for a Fecal Helicobacter pylori Antigen. CVI 9: 75-78 [Abstract] [Full Text]  
• Uchida, K., Okazaki, K., Debrecceni, A., Nishi, T., Iwano, H., Inai, M., Uose, S., Nakase, H., Ohana, M., Oshima, C., Matsushima, Y., Kawanami, C., Hiai, H., Masuda, T., Chiba, T. (2001). Analysis of Cytokines in the Early Development of Gastric Secondary Lymphoid Follicles in Helicobacter pylori-Infected BALB/c Mice with Neonatal Thymectomy. Infect. Immun. 69: 6749-6754 [Abstract] [Full Text]  
• Lacy, B. E., Rosemore, J. (2001). Helicobacter pylori: Ulcers and More: The Beginning of an Era. J. Nutr. 131: 2789S-2793 [Abstract] [Full Text]  
• Chey, W. D., Fendrick, A. M. (2001). Noninvasive Helicobacter pylori Testing for the "Test-and-Treat" Strategy: A Decision Analysis to Assess the Effect of Past Infection on Test Choice. Arch Intern Med 161: 2129-2132 [Abstract] [Full Text]  
• Muhlestein, J. B., Anderson, J. L., Carlquist, J. F., Salunkhe, K., Horne, B. D., Pearson, R. R., Bunch, T. J., Allen, A., Trehan, S., Nielson, C. (2000). Randomized Secondary Prevention Trial of Azithromycin in Patients With Coronary Artery Disease : Primary Clinical Results of the ACADEMIC Study. Circulation 102: 1755-1760 [Abstract] [Full Text]  
• Icatlo, F. C. Jr., Kimura, N., Goshima, H., Kodama, Y. (2000). Enhanced Reduction of Helicobacter pylori Load in Precolonized Mice Treated with Combined Famotidine and Urease-Binding Polysaccharides. Antimicrob. Agents Chemother. 44: 2492-2497 [Abstract] [Full Text]  
• Kato, M., Yamaoka, Y., Kim, J. J., Reddy, R., Asaka, M., Kashima, K., Osato, M. S., El-Zaatari, F. A. K., Graham, D. Y., Kwon, D. H. (2000). Regional Differences in Metronidazole Resistance and Increasing Clarithromycin Resistance among Helicobacter pylori Isolates from Japan. Antimicrob. Agents Chemother. 44: 2214-2216 [Abstract] [Full Text]  
• Braden, B., Posselt, H.-G., Ahrens, P., Kitz, R., Dietrich, C. F., Caspary, W. F. (2000). New Immunoassay in Stool Provides an Accurate Noninvasive Diagnostic Method for Helicobacter pylori Screening in Children. Pediatrics 106: 115-117 [Abstract] [Full Text]  
• Bursey, F., Crowley, M., Janes, C., Turner, C. J. (2000). Cost analysis of a provincial drug program to guide the treatment of upper gastrointestinal disorders. CMAJ 162: 817-823 [Abstract] [Full Text]  
• Maeda, S., Yoshida, H., Matsunaga, H., Ogura, K., Kawamata, O., Shiratori, Y., Omata, M. (2000). Detection of Clarithromycin-Resistant Helicobacter pylori Strains by a Preferential Homoduplex Formation Assay. J. Clin. Microbiol. 38: 210-214 [Abstract] [Full Text]  
• Quaschning, T., Wanner, C. (1999). The role of Chlamydia in coronary heart disease--fact or fiction?. Nephrol Dial Transplant 14: 2800-2803 [Full Text]  
• Debets-Ossenkopp, Y. J., Pot, R. G. J., van Westerloo, D. J., Goodwin, A., Vandenbroucke-Grauls, C. M. J. E., Berg, D. E., Hoffman, P. S., Kusters, J. G. (1999). Insertion of Mini-IS605 and Deletion of Adjacent Sequences in the Nitroreductase (rdxA) Gene Cause Metronidazole Resistance in Helicobacter pylori NCTC11637. Antimicrob. Agents Chemother. 43: 2657-2662 [Abstract] [Full Text]  
• Greenberg, P. D., Cello, J. P. (1999). Lack of Effect of Treatment for Helicobacter pylori on Symptoms of Nonulcer Dyspepsia. Arch Intern Med 159: 2283-2288 [Abstract] [Full Text]  
• Zhao, X.-J., Koyama, E., Ishizaki, T. (1999). An In Vitro Study on the Metabolism and Possible Drug Interactions of Rokitamycin, a Macrolide Antibiotic, Using Human Liver Microsomes. Drug Metab. Dispos. 27: 776-785 [Abstract] [Full Text]  
• Hassan, I. J., Stark, R. M., Greenman, J., Millar, M. R. (1999). Activities of beta -Lactams and Macrolides against Helicobacter pylori. Antimicrob. Agents Chemother. 43: 1387-1392 [Abstract] [Full Text]  
• Debets-Ossenkopp, Y. J., Herscheid, A. J., Pot, R. G. J., Kuipers, E. J., Kusters, J. G., Vandenbroucke-Grauls, C. M. J. E. (1999). Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother 43: 511-515 [Abstract] [Full Text]  
• Anderson, J. L., Muhlestein, J. B., Carlquist, J., Allen, A., Trehan, S., Nielson, C., Hall, S., Brady, J., Egger, M., Horne, B., Lim, T. (1999). Randomized Secondary Prevention Trial of Azithromycin in Patients With Coronary Artery Disease and Serological Evidence for Chlamydia pneumoniae Infection : The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study. Circulation 99: 1540-1547 [Abstract] [Full Text]  
• Hood, H. M., Wark, C., Burgess, P. A., Nicewander, D., Scott, M. W. (1999). Screening for Helicobacter pylori and Nonsteroidal Anti-inflammatory Drug Use in Medicare Patients Hospitalized With Peptic Ulcer Disease. Arch Intern Med 159: 149-154 [Abstract] [Full Text]  
• Fisher, R. S., Parkman, H. P. (1998). Management of Nonulcer Dyspepsia. NEJM 339: 1376-1381 [Full Text]  
• Debets-Ossenkopp, Y. J., Brinkman, A. B., Kuipers, E. J., Vandenbroucke-Grauls, C. M. J. E., Kusters, J. G. (1998). Explaining the Bias in the 23S rRNA Gene Mutations Associated with Clarithromycin Resistance in Clinical Isolates of Helicobacter pylori. Antimicrob. Agents Chemother. 42: 2749-2751 [Abstract] [Full Text]  
• Ando, T., Kusugami, K., Ohsuga, M., Ina, K., Shinoda, M., Konagaya, T., Sakai, T., Imada, A., Kasuga, N., Nada, T., Ichiyama, S., Blaser, M. J. (1998). Differential Normalization of Mucosal Interleukin-8 and Interleukin-6 Activity after Helicobacter pylori Eradication. Infect. Immun. 66: 4742-4747 [Abstract] [Full Text]  
• Karat, D, Griffin, S M (1998). Helicobacter pylori and surgery. BMJ 317: 679-679 [Full Text]  
• Maeda, S, Yoshida, H, Ogura, K, Kanai, F, Shiratori, Y, Omata, M (1998). Helicobacter pylori specific nested PCR assay for the detection of 23S rRNA mutation associated with clarithromycin resistance. Gut 43: 317-321 [Abstract] [Full Text]  
• Anderson, J. L., Carlquist, J. F., Muhlestein, J. B., Horne, B. D., Elmer, S. P. (1998). Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol 32: 35-41 [Abstract] [Full Text]  
• Salcedo, J. A., Al-Kawas, F. (1998). Treatment of Helicobacter pylori Infection. Arch Intern Med 158: 842-851 [Abstract] [Full Text]  
• de Boer, W. A., Molmenti, E. P. (1997). Perforated Duodenal Ulcer. NEJM 337: 1013-1013 [Full Text]  
• Munnangi, S., Sonnenberg, A. (1997). Time Trends of Physician Visits and Treatment Patterns of Peptic Ulcer Disease in the United States. Arch Intern Med 157: 1489-1494 [Abstract]  
• Roll, J., Weng, A., Newman, J. (1997). Diagnosis and Treatment of Helicobacter pylori Infection Among California Medicare Patients. Arch Intern Med 157: 994-998 [Abstract]  
• Monkemuller, K. E., Genta, R. M., Graham, D. Y. (1996). Treatment of Helicobacter pylori Infection. NEJM 335: 1843-1844 [Full Text]  
• Sniffen, J. C., Walsh, J. H., Peterson, W. L. (1996). Treatment of Helicobacter pylori Infection in Peptic Ulcer Disease. NEJM 334: 474-474 [Full Text]